Publication:
Nine versus 52 weeks of adjuvant trastuzumab in early breast cancer: An observational study of the Turkish Oncology Group.

Simple item page
dc.contributor.authorsIcli, F.; Altundag, K.; Coskun, U.; Paydas, S.; Basaran, G.; Saip, P.; Dogu, G. G.; Eralp, Y.; Uslu, R.; Sevinc, A.; Onur, H.; Mandel, N. M.; Sezgin, C.; Altinbas, M.; Guler, N.; Isikdogan, A.; Gokmen, E.; Uygun, K.; Ustuner, Z.; Yaren, A.
dc.date.accessioned2022-03-10T17:50:54Z
dc.date.accessioned2026-01-11T06:38:46Z
dc.date.available2022-03-10T17:50:54Z
dc.date.issued2011
dc.identifier.doi10.1200/jco.2011.29.15_suppl.629
dc.identifier.eissn1527-7755
dc.identifier.issn0732-183X
dc.identifier.urihttps://hdl.handle.net/11424/221413
dc.identifier.wosWOS:000208880300132
dc.language.isoeng
dc.publisherAMER SOC CLINICAL ONCOLOGY
dc.relation.ispartofJOURNAL OF CLINICAL ONCOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.titleNine versus 52 weeks of adjuvant trastuzumab in early breast cancer: An observational study of the Turkish Oncology Group.
dc.typeconferenceObject
dc.type.submeetingabstract
dspace.entity.typePublication
oaire.citation.issue15
oaire.citation.titleJOURNAL OF CLINICAL ONCOLOGY
oaire.citation.volume29

Files

Collections

Araştırma Çıktıları